Gallbladder and Biliary Disease

Gallbladder and Biliary Disease News

  • PPI Use and Risk of Hepatic Encephalopathy in Cirrhotic Patients Patients with cirrhosis who are treated with a proton pump inhibitor (PPI) face an increased risk of hepatic encephalopathy, and the risk rises in a dose-dependent fashion, a large study from Taiwan has found.
  • Allergan to Buy Tobira in Push for NASH Treatments Allergan Plc said it would buy Tobira Therapeutics Inc in a deal worth up to $1.7 billion, about 19 times the company's current value, to get a leg up in the race to develop therapies for nonalcoholic steatohepatitis (NASH).

Gallbladder and Biliary Disease Perspective



All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.